| HORIZON | TRADES | WIN RATE | INSIDER RETURN | SPY RETURN | MEAN EXCESS | MEDIAN EXCESS | T-STAT |
|---|---|---|---|---|---|---|---|
| 7d | 1 | +0.00% | -4.01% | -1.03% | -2.98% | -2.98% | — |
| 14d | 1 | +0.00% | -8.39% | +0.55% | -8.94% | -8.94% | — |
| 30d | 1 | +100.00% | +3.84% | +0.35% | +3.49% | +3.49% | — |
| 60d | 1 | +0.00% | -16.21% | -0.43% | -15.79% | -15.79% | — |
| 90d | 1 | +0.00% | -20.66% | -6.55% | -14.11% | -14.11% | — |
| 180d | 1 | +100.00% | +18.90% | +6.27% | +12.63% | +12.63% | — |
| 1y | 1(1 pending) | — | — | — | — | — | — |
| 2y | 1(1 pending) | — | — | — | — | — | — |
| COMPANY | TYPE | SHARES | PRICE | VALUE | HELD AFTER | TRADE DATE | FILED | DETAILS |
|---|---|---|---|---|---|---|---|---|
| MNPR MONOPAR THERAPEUTICS | PURCHASE Chief Financial Officer | 1,228 | — | — | 2,728 | Jun 30, 2026 | Jul 2, 2026 ↗ | View → |
| MNPR MONOPAR THERAPEUTICS | SALE Chief Financial Officer | 507 | $92.59 | $46.9K | 2,221 | Jun 30, 2026 | Jul 2, 2026 ↗ | View → |
| MNPR MONOPAR THERAPEUTICS | SALE Chief Financial Officer | 1,228 | — | — | 8,598 | Jun 30, 2026 | Jul 2, 2026 ↗ | View → |
| MNPR MONOPAR THERAPEUTICS | PURCHASE Chief Financial Officer | 1,500 | $69.95 | $104.9K | 1,500 | Dec 26, 2025 | Dec 29, 2025 ↗ | View → |
| MNPR MONOPAR THERAPEUTICS | PURCHASEGRANT Stock grant | 9,826 | — | — | 9,826 | Dec 2, 2025 | Dec 8, 2025 ↗ | View → |
| MNPR MONOPAR THERAPEUTICS | PURCHASEGRANT Stock grant | 7,135 | — | — | 7,135 | Dec 2, 2025 | Dec 8, 2025 ↗ | View → |
| MNPR MONOPAR THERAPEUTICS | PURCHASEGRANT Stock grant | 25,000 | — | — | 25,000 | Mar 3, 2025 | Mar 5, 2025 ↗ | View → |